The study introduces a novel Gck Knockin mouse model (GCK‑MODY) with reduced glucokinase activity. Heterozygous mice exhibit mild hyperglycemia, while homozygous mutants develop overt diabetes. Combination therapy using dorzagliatin (a GK activator) and a GLP‑1 receptor agonist improves glucose tolerance in both this model and db/db mice. Additive effects are sex-dependent, with greater benefit in males.
Dorzagliatin and GLP‑1 receptor agonists act synergistically to improve glycemic control in GCK‑MODY and obese diabetic mice, with sex-specific response profiles
Gck^IRES-reporter Knockin mouse — genOway-developed, mimicking GCK-MODY, IRES-based reporter insertion
GCK-MODY, glucokinase activators, GLP-1 agonists, type 2 diabetes, metabolic disease, precision medicine
Reporter knockin allele with IRES cassette at Gck locus, reduction in glucokinase activity confirmed by aberrant splicing, phenotype characterization of heterozygous and homozygous animals, glucose tolerance testing, drug treatment studies in both Gck and db/db mice, analysis of sex differences in response
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
